NASDAQ:CBLL CeriBell (CBLL) Stock Price, News & Analysis $18.38 -0.12 (-0.65%) Closing price 04:00 PM EasternExtended Trading$18.38 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CeriBell Stock (NASDAQ:CBLL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CeriBell alerts:Sign Up Key Stats Today's Range$18.25▼$18.9350-Day Range$16.30▼$21.3352-Week Range$10.85▼$24.33Volume251,480 shsAverage Volume317,589 shsMarket Capitalization$697.34 millionP/E RatioN/ADividend YieldN/APrice Target$22.20Consensus RatingModerate Buy Company Overview CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention. The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows. CeriBell devices typically feature automated test protocols, digital signal processing and connectivity options for integration with electronic health record systems. These diagnostic platforms are engineered to meet regulatory requirements in multiple jurisdictions and are complemented by service contracts and technical support offerings. CeriBell has developed a global presence through direct sales and distribution partnerships across North America, Europe and select international markets. By collaborating with healthcare providers, clinical laboratories and research institutions, the company focuses on refining screening protocols, delivering training resources and expanding access to early hearing assessment solutions. CeriBell’s commitment to innovation and clinical validation underpins its mission to reduce the incidence of undiagnosed hearing loss in newborns and support positive developmental outcomes in pediatric populations.AI Generated. May Contain Errors. Read More CeriBell Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCBLL MarketRank™: CeriBell scored higher than 50% of companies evaluated by MarketBeat, and ranked 562nd out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCeriBell has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCeriBell has a consensus price target of $22.20, representing about 20.8% upside from its current price of $18.38.Amount of Analyst CoverageCeriBell has only been the subject of 2 research reports in the past 90 days.Read more about CeriBell's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CeriBell are expected to grow in the coming year, from ($1.69) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CeriBell is -11.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CeriBell is -11.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCeriBell has a P/B Ratio of 4.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CeriBell's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.34% of the float of CeriBell has been sold short.Short Interest Ratio / Days to CoverCeriBell has a short interest ratio ("days to cover") of 7.28.Change versus previous monthShort interest in CeriBell has recently decreased by 2.06%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCeriBell does not currently pay a dividend.Dividend GrowthCeriBell does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.87 News SentimentCeriBell has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CeriBell this week, compared to 4 articles on an average week. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CeriBell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,877,244.00 in company stock.Percentage Held by Insiders20.10% of the stock of CeriBell is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCeriBell has minimal institutional ownership at this time.Read more about CeriBell's insider trading history. Receive CBLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CeriBell and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CBLL Stock News HeadlinesCeribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological OutcomesJune 8 at 7:00 AM | globenewswire.comCeriBell Charts Growth in Acute Care EEG as Pediatrics, Delirium Expand MarketJune 7 at 1:02 AM | americanbankingnews.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.June 10 at 1:00 AM | Brownstone Research (Ad)Ceribell Announces Director Elections at 2026 Annual MeetingJune 2, 2026 | tipranks.comInsider Selling: CeriBell (NASDAQ:CBLL) VP Sells 862 Shares of StockMay 27, 2026 | insidertrades.comCeribell to Participate in the William Blair 46th Annual Growth Stock ConferenceMay 20, 2026 | globenewswire.comBank of America Securities Remains a Buy on Ceribell, Inc. (CBLL)May 19, 2026 | theglobeandmail.comCeriBell sees 'early innings' growth as hospital accounts and usage hit recordsMay 15, 2026 | msn.comSee More Headlines CBLL Stock Analysis - Frequently Asked Questions How have CBLL shares performed this year? CeriBell's stock was trading at $21.93 at the beginning of 2026. Since then, CBLL stock has decreased by 16.2% and is now trading at $18.38. How were CeriBell's earnings last quarter? CeriBell, Inc. (NASDAQ:CBLL) posted its earnings results on Monday, May, 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.13. The business earned $26.49 million during the quarter, compared to analysts' expectations of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative trailing twelve-month return on equity of 38.19%. Read the conference call transcript. When did CeriBell IPO? CeriBell (CBLL) raised $159 million in an initial public offering on Friday, October 11th 2024. The company issued 10,606,060 shares at $14.00-$16.00 per share. Who are CeriBell's major shareholders? CeriBell's top institutional shareholders include KCM Capital Inc (3.69%), Bank of New York Mellon Corp (3.06%), Redmile Group LLC (1.02%) and Peregrine Capital Management LLC (0.92%). Insiders that own company stock include Xingjuan Chao, Josef Parvizi, Raymond Woo, Scott Blumberg, Joseph S Manni, David Foehr, Rebecca B Robertson and William W Burke. View institutional ownership trends. How do I buy shares of CeriBell? Shares of CBLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/11/2026Today6/10/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 6 days, CBLL's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CBLL Previous SymbolNASDAQ:CBLL CIK1861107 WebN/A Phone(800) 436-0826FaxN/AEmployeesN/AYear Founded2014Price Target and Rating Average Price Target for CeriBell$22.20 High Price Target$30.00 Low Price Target$17.00 Potential Upside/Downside+20.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$53.41 million Net Margins-63.51% Pretax Margin-63.51% Return on Equity-38.19% Return on Assets-30.92% Debt Debt-to-Equity Ratio0.14 Current Ratio10.44 Quick Ratio10.01 Sales & Book Value Annual Sales$89.06 million Price / Sales7.83 Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book4.39Miscellaneous Outstanding Shares37,940,000Free Float30,316,000Market Cap$697.34 million OptionableN/A Beta0.84 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CBLL) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredLive demo of Elon Musk’s AI agentJeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...Brownstone Research | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredThe part that convinced me Joel is legitMost trading gurus cite big win rates but won't let you verify them. Joel Peterson is different - his trade pl...Crypto Swap Profits | SponsoredImportant SpaceX PREDICTIONThe biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CeriBell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CeriBell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
